Selective delivery of rifampicin incorporated into poly(dl-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guérin

Microbes and Infection

Volumn 8, Issue 9-10, 2006, Pages 2484-2491

  Yoshida, Aya ^a   Matumoto, Makoto ^b   Hshizume, Hiroyuki ^a,b   Oba, Yoshiro ^b   Tomishige, Tatuo ^b   Inagawa, Hiroyuki ^c,d,e   Kohchi, Chie ^c,d   Hino, Mami ^c   Ito, Fuminori ^d   Tomoda, Keishiro ^d   Nakajima, Takehisa ^d   Makino, Kimiko ^d   Terada, Hiroshi ^d   Hori, Hitoshi ^a   Soma, Gen Ichiro ^c,d  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

^e NATIONAL FISHERIES UNIVERSITY   (Japan)

Author keywords

Drug delivery systems; Macrophages; Mycobacterium bovis; Phagocytosis; Poly(dl lactic co glycolic) acid; Tuberculosis

Indexed keywords

GLYCOLIC ACID; LACTIC ACID; MICROSPHERE; MONOMER; POLYGLACTIN; RIFAMPICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; CELL TRANSPORT; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; IN VIVO STUDY; INTRACELLULAR SPACE; LUNG ALVEOLUS MACROPHAGE; LUNG GRANULOMA; LUNG LOBE; MOLECULAR SIZE; MOLECULAR WEIGHT; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; TARGET CELL; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CATTLE; CHEMISTRY, PHYSICAL; DRUG DELIVERY SYSTEMS; MACROPHAGES, ALVEOLAR; MICROSPHERES; MYCOBACTERIUM BOVIS; PHYSICOCHEMICAL PHENOMENA; POLYESTERS; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN; TUBERCULOSIS, BOVINE;

BACILLI (CLASS); MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS;

EID: 33749343333     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2006.06.004     Document Type: Article

References (11)

1. Russell D.G. Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell Biol. 2 (2001) 569-577
2. Teo S.K. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Int. J. Tuberc. Lung Dis. 3 (1999) 126-132
3. Barrow E.L., Winchester G.A., Staas J.K., Quenelle D.C., and Barrow W.W. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob. Agents Chemother. 42 (1998) 2682-2689
4. Ul-Ain Q., Sharma S., and Khuller G.K. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. Antimicrob. Agents Chemother. 47 (2003) 3005-3007
5. Labana S., Pandey R., Sharma S., and Khuller G.K. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int. J. Antimicrob. Agents 20 (2002) 301-304
6. Pandey R., Sharma S., and Khuller G.K. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis. Int. J. Antimicrob. Agents 23 (2004) 414-415
7. Quenelle D.C., Winchester G.A., Staas J.K., Barrow E.L., and Barrow W.W. Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. Antimicrob. Agents Chemother. 45 (2001) 1637-1644
8. Makino K., Nakajima T., Shikamura M., Ito F., Ando S., Kochi C., Inagawa H., Soma G., and Terada H. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin, Colloids Surf. B Biointerfaces 36 (2004) 35-42
9. Suarez S., O'Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., and Hickey A.J. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm. Res. 18 (2001) 1315-1319
10. Sahoo S.K., Panyam J., Prabha S., and Labhasetwar V. Residual polyvinyl alcohol associated with poly (D, L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Controlled Release 82 (2002) 105-114
11. Sharma R., Saxena D., Dwivedi A.K., and Misra A. Inhalable microparticles containing drug combinations to targ et al. veolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 18 (2001) 1405-1410